According to Zhitong Finance App, Pearl Pharmaceutical (01513) announced that in the first three quarters of 2026, operating revenue was 7.319 billion yuan, down 19.71% year on year; net profit attributable to shareholders of listed companies was 1,288 billion yuan, down 26.57% year on year; basic earnings per share were 1.45 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.